In addition to low-energy-threshold images (TLIs), photon-counting detector (PCD) computed tomography (CT) can generate virtual monoenergetic images (VMIs) and iodine maps. Our study sought to determine the image type that maximizes iodine detectability. Adult abdominal phantoms with iodine inserts of various concentrations and lesion sizes were scanned on a PCD-CT system. TLIs, VMIs at 50 keV, and iodine maps were generated, and iodine contrast-to-noise ratio (CNR) was measured. A channelized Hotelling observer was used to determine the area under the receiver-operating-characteristic curve (AUC) for iodine detectability. Iodine map CNR (0.57 ± 0.42) was significantly higher (P < 0.05) than for TLIs (0.46 ± 0.26) and lower (P < 0.001) than for VMIs at 50 keV (0.74 ± 0.33) for 0.5 mgI/cc and a 35-cm phantom. For the same condition and an 8-mm lesion, iodine detectability from iodine maps (AUC = 0.95 ± 0.01) was significantly lower (P < 0.001) than both TLIs (AUC = 0.99 ± 0.00) and VMIs (AUC = 0.99 ± 0.01). VMIs at 50 keV had similar detectability to TLIs and both outperformed iodine maps. The lowest detectable iodine concentration was 0.5 mgI/cc for an 8-mm lesion and 1.0 mgI/cc for a 4-mm lesion.
Photon counting detector (PCD) based multi-energy CT is able to generate different types of images such as virtual monoenergetic images (VMIs) and material specific images (e.g., iodine maps) in addition to the conventional single energy images. The purpose of this study is to determine the image type that has optimal iodine detection and to determine the lowest detectable iodine concentration using a PCD-CT system. A 35 cm body phantom with iodine inserts of 4 concentrations and 2 sizes was scanned on a research PCD-CT system. For each iodine concentration, 80 repeated scans were performed and images were reconstructed for each energy threshold. In addition, VMIs at different keVs and iodine maps were also generated. CNR was measured for each type of images. A channelized Hotelling observer was used to assess iodine detectability after being validated with human observer studies, with area under the ROC curve (AUC) as a figure of merit. The agreement between model and human observer performance indicated that model observer could serve as an effective approach to determine optimal image type for the clinical practice and to determine the lowest detectable iodine concentration. Results demonstrated that for all size and concentration combinations, VMI at 70 keV had similar performance as that of threshold low images, both of which outperformed the iodine map images. At the AUC value of 0.8, iodine concentration as low as 0.2 mgI/cc could be detected for an 8 mm object and 0.5 mgI/cc for a 4 mm object with a 5 mm slice thickness.
Researchers employ increasingly complex sub-micron particles for oncological applications to deliver bioactive
therapeutic or imaging compounds to known and unknown in vivo tumor targets. These particles are often
manufactured using a vast array of compounds and techniques resulting in a complex architecture, which can be
quantified ex vivo by conventional metrology and chemical assays. In practice however, experimental homogeneity
using nanoparticles can be difficult to achieve. While several imaging techniques have been previously shown to
follow the accumulation of nanoparticles into tumor targets, a more rapid sensor that provides a quantifiable estimate
of dose delivery and short-term systemic response could increase the clinical efficacy and greatly reduce the
variability of these treatments. We have developed an optical device, the pulse photometer, that when placed on an
accessible location will estimate the vascular concentration of near-infrared extinguishing nanoparticles in murine
subjects. Using a technique called multi-wavelength photoplethysmography, the same technique used in pulse
oximetry, our pulse photometer requires no baseline for each estimate allowing it to be taken on and off of the
subject several times during experiments employing long circulating nanoparticles. We present a formal study of
our prototype instrument in which circulation half-life and nanoparticle concentration of gold nanorods is
determined in murine subjects with the aid of light anesthesia. In this study, we show good agreement between
vascular nanorod concentrations (given in optical density) as determined by our device and with UV-VIS
spectrophotometry using low volume blood samples.
There is an urgent clinical need to monitor the intravenous delivery and bioavailability of circulating nanoparticles used in cancer therapy. This work presents the use of photoplethysmography for the noninvasive real-time estimation of vascular gold nanoshell concentration in a murine subject. We develop a pulse photometer capable of accurately measuring the photoplethysmogram in mice and determining the ratio of pulsatile changes in optical extinction between 805 and 940 nm, commonly referred to as R. These wavelengths are selected to correspond to the extinction properties of gold nanoshells. Six 30-s measurements (5 min, 2, 4, 6, 8, 10 h) are taken under light anesthesia to observe the change in R as the nanoparticles clear from the circulation. Our model describes the linear fit (R2=0.85) between R and the concentration of nanoparticles measured via ex vivo spectrophotometric and instrumental neutron activation analysis. This demonstrates the utility of this technique in support of clinical nanoparticle therapies.
Researchers employ increasingly complex sub-micron particles for oncological applications to deliver bioactive
therapeutic or imaging compounds to known and unknown in vivo tumor targets. In practice, experimental homogeneity
using nanoparticles can be difficult to achieve. While several imaging techniques have been previously shown to follow
the accumulation of nanoparticles into tumor targets, a more rapid sensor that provides a quantifiable estimate of dose
delivery and short-term systemic response could increase the clinical efficacy and greatly reduce the variability of these
treatments. We have developed a pulse photometer that when placed on an optically accessible location will estimate the
concentration of near-infrared absorbing nanoparticles. The goal is to monitor the accuracy of the delivered dose and the
effective circulation time of nanoparticles immediately after intravenous delivery but prior to therapeutic intervention.
We present initial tests of our prototype using murine models to assess its ability to quantify circulation half-life and
nanoparticle concentration. Four mice were injected with nanoparticles and circulation half-life estimates ranged from 3-
43 minutes. UV-Vis spectrophotometry was used to independently verify these measurements using 5μL blood samples.
Linear models relating the two methods produced R2 values of 0.91, 0.99, 0.88, and 0.24.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.